SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-139510
Filing Date
2024-05-15
Accepted
2024-05-15 17:16:02
Documents
15
Period of Report
2024-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d825172d8k.htm   iXBRL 8-K 24845
2 EX-99.1 d825172dex991.htm EX-99.1 39428
6 GRAPHIC g825172g0514053126812.jpg GRAPHIC 3027
  Complete submission text file 0001193125-24-139510.txt   201969

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alrn-20240515.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20240515_lab.xml EX-101.LAB 18758
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20240515_pre.xml EX-101.PRE 11715
19 EXTRACTED XBRL INSTANCE DOCUMENT d825172d8k_htm.xml XML 3808
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 24952570
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)